Information Provided By:
Fly News Breaks for January 31, 2020
VRTX
Jan 31, 2020 | 07:16 EDT
H.C. Wainwright analyst Andrew Fein raised his price target for Vertex Pharmaceuticals to $270 from $220 and maintains a Buy rating on the shares. The analyst says that as Trikafta traction "remains in its infancy," he looks ahead for cash flow in 2020.